NAS:AVDL (Ireland)  
Avadel Pharmaceuticals PLC logo

Avadel Pharmaceuticals PLC

$ 8.93 -0.35 (-3.77%) 12:00 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 528.83M
Enterprise V:
$ 605.11M
Volume:
469.48K
Avg Vol (2M):
827.77K
Also Trade In:
Volume:
469.48K
Market Cap $:
528.83M
PE Ratio:
At Loss
Avg Vol (2-Month):
827.77K
Enterprise Value $:
605.11M
PB Ratio:
0
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.77
Equity-to-Asset -0.09
Debt-to-Equity -11.12
Debt-to-EBITDA -1.44
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Beneish M-Score -5.32
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 64.61
9-Day RSI 65.39
14-Day RSI 64.52
6-1 Month Momentum % 152.81
12-1 Month Momentum % -20.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.73
Quick Ratio 2.73
Cash Ratio 2.56

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -16.3

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -6.22
EV-to-EBITDA -6.3
EV-to-Forward-Revenue 15.58
EV-to-FCF -7.81
Earnings Yield (Greenblatt) % -16.08

Financials (Next Earnings Date:2023-03-17 Est.)

AVDL's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:AVDL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.23
Beta 1.52
Volatility % 143.74
14-Day RSI 64.52
14-Day ATR ($) 0.788978
20-Day SMA ($) 7.6705
12-1 Month Momentum % -20.77
52-Week Range ($) 1.05 - 10.02
Shares Outstanding (Mil) 61.78

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Avadel Pharmaceuticals PLC Filings

Document Form Filing Date
No Filing Data

Avadel Pharmaceuticals PLC Analysis

Share your research

Headlines

See More
No news.